Data from Phase 2 PILOT Study of Bristol Myers Squibb’s CAR T cell Therapy Breyanzi Show Substantial…
Bristol Myers Squibb announced results from the primary analysis of PILOT, a multicenter, Phase 2 study evaluating Breyanzi (lisocabtagene maraleucel)…